New combo therapy shows promise for slowing spread of prostate cancer
NCT ID NCT04037358
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a radioactive drug (Radium-223) to targeted radiation (SABR) helps men with prostate cancer that has spread to a few bones or soft tissues. 64 men participated, receiving either SABR alone or SABR plus Radium-223. The goal was to see if the combination delays cancer progression longer than SABR alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins
Baltimore, Maryland, 21287, United States